Literature DB >> 30071024

Correction: Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications.

Page Axley, Sandhya Mudumbi, Shabnam Sarker, Yong-Fang Kuo, Ashwani K Singal.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0197117.].

Entities:  

Year:  2018        PMID： 30071024      PMCID： PMC6071973          DOI： 10.1371/journal.pone.0199402

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


The fifth author’s middle initial is missing. The correct name is: Ashwani K. Singal. The correct citation is: Axley P, Mudumbi S, Sarker S, Kuo Y-F, Singal AK (2018) Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS ONE 13(5): e0197117. https://doi.org/10.1371/journal.pone.0197117
  1 in total

1.  Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications.

Authors:  Page Axley; Sandhya Mudumbi; Shabnam Sarker; Yong-Fang Kuo; Ashwani K Singal
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240
  1 in total
  1 in total

Review 1.  Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.

Authors:  Sharin E Roth; Mark I Avigan; David Bourdet; David Brott; Rachel Church; Ajit Dash; Douglas Keller; Philip Sherratt; Paul B Watkins; Lucas Westcott-Baker; Silvia Lentini; Michael Merz; Lila Ramaiah; Shashi K Ramaiah; Ann Marie Stanley; John Marcinak
Journal:  Clin Pharmacol Ther       Date:  2019-09-14       Impact factor: 6.875
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.